Phase 1 Study of ZM008, an Anti-LLT1 Antibody, Alone and Combined with Toripalimab for Adults with Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating ZM008, an anti-LLT1 antibody, alone and combined with Toripalimab, for patients with advanced solid tumors who have no standard treatment options left or cannot tolerate them. This phase 1 dose escalation trial focuses on assessing safety and dosage levels in patients with various cancers including lung, breast, head and neck, prostate, colorectal, pancreatic, ovarian, lymphoma, kidney, and urothelial cancers. The study involves giving ZM008 intravenously by itself initially, followed by combination treatment with Toripalimab. The treatment cycles are 21 days long, and patients will receive escalating doses to find the appropriate dose level. The trial has a single experimental arm with dose escalation of ZM008 alone and then combined with Toripalimab. Participants will be monitored through screening and treatment cycles for up to 90 days after their last dose, with assessments including vital signs such as blood pressure, heart rate, temperature, and oxygen levels. Blood samples will be collected to study drug levels and immune response. Researchers will also track tumor response and progression for up to 36 months. Safety and side effects will be carefully observed throughout the study period.

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors